Quince Therapeutics, Inc. Stock-Based Compensation
Quince Therapeutics, Inc. (QNCX) reported Stock-Based Compensation of $13.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- Quince Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $12.09M, a 849.96% increase year-over-year.
- Quince Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.29M, a 7.22% decline year-over-year.
- Quince Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.19M, a 5.87% increase year-over-year.
- Quince Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.25M, a 11.65% increase year-over-year.
- Quince Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $5.11M, a 7.56% increase from fiscal 2024.
- Quince Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $4.75M, a 9.08% decline from fiscal 2023.
- Quince Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $5.22M, a 68.59% decline from fiscal 2022.
- Quince Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $16.62M, a 44.33% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $13.38M 10-Q · filed 2026-08-14 | $14.57M derived: sum of 3 quarters · filed 2026-08-14 | $15.82M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.29M 10-Q · filed 2026-05-11 | $2.48M derived: sum of 2 quarters · filed 2026-05-11 | $3.73M derived: sum of 3 quarters · filed 2026-05-11 | $5.00M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $2.45M derived: sum of 2 quarters · filed 2026-04-10 | $3.72M derived: sum of 3 quarters · filed 2026-08-14 | $5.11M 10-K · filed 2026-04-10 |
| 2025-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.53M derived: sum of 2 quarters · filed 2026-08-14 | $3.91M 10-Q · filed 2025-11-12 | $5.04M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $2.66M 10-Q · filed 2026-08-14 | $3.78M derived: sum of 3 quarters · filed 2026-08-14 | $4.91M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.39M 10-Q · filed 2026-05-11 | $2.51M derived: sum of 2 quarters · filed 2026-05-11 | $3.63M derived: sum of 3 quarters · filed 2026-05-11 | $4.86M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $2.25M derived: sum of 2 quarters · filed 2026-04-10 | $3.47M derived: sum of 3 quarters · filed 2026-04-10 | $4.75M 10-K · filed 2026-04-10 |
| 2024-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.35M derived: sum of 2 quarters · filed 2025-11-12 | $3.62M 10-Q · filed 2025-11-12 | $4.71M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $2.50M 10-Q · filed 2025-08-11 | $3.58M derived: sum of 3 quarters · filed 2025-08-11 | $4.91M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $1.27M 10-Q · filed 2025-05-13 | $2.36M derived: sum of 2 quarters · filed 2025-05-13 | $3.69M derived: sum of 3 quarters · filed 2025-05-13 | $5.01M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $2.42M derived: sum of 2 quarters · filed 2025-03-24 | $3.74M derived: sum of 3 quarters · filed 2025-03-24 | $5.22M 10-K · filed 2025-03-24 |
| 2023-09-30 | $1.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.65M derived: sum of 2 quarters · filed 2024-11-13 | $4.13M 10-Q · filed 2024-11-13 | $5.77M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.80M 10-Q · filed 2024-08-13 | $4.43M derived: sum of 3 quarters · filed 2024-08-13 | $5.13M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.48M 10-Q · filed 2024-05-13 | $3.11M derived: sum of 2 quarters · filed 2024-05-13 | $3.81M derived: sum of 3 quarters · filed 2024-05-13 | $8.86M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $2.33M derived: sum of 2 quarters · filed 2024-04-01 | $7.38M derived: sum of 3 quarters · filed 2024-04-01 | $16.62M 10-K · filed 2024-04-01 |
| 2022-09-30 | $694.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $5.75M derived: sum of 2 quarters · filed 2023-11-14 | $14.99M 10-Q · filed 2023-11-14 | $23.48M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $5.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $14.29M 10-Q · filed 2023-08-03 | $22.79M derived: sum of 3 quarters · filed 2023-08-03 | $30.40M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $9.24M 10-Q · filed 2023-05-15 | $17.73M derived: sum of 2 quarters · filed 2023-05-15 | $25.35M derived: sum of 3 quarters · filed 2023-05-15 | $32.10M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $8.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $16.11M derived: sum of 2 quarters · filed 2023-03-15 | $22.86M derived: sum of 3 quarters · filed 2023-03-15 | $29.85M 10-K · filed 2023-03-15 |
| 2021-09-30 | $7.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $14.37M derived: sum of 2 quarters · filed 2022-11-09 | $21.36M 10-Q · filed 2022-11-09 | $26.32M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $6.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $13.74M 10-Q · filed 2022-08-09 | $18.70M derived: sum of 3 quarters · filed 2022-08-09 | $22.86M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $6.99M 10-Q · filed 2022-05-10 | $11.95M derived: sum of 2 quarters · filed 2022-05-10 | $16.11M derived: sum of 3 quarters · filed 2022-05-10 | $19.51M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $9.12M derived: sum of 2 quarters · filed 2022-03-01 | $12.52M derived: sum of 3 quarters · filed 2022-03-01 | $14.47M 10-K · filed 2022-03-01 |
| 2020-09-30 | $4.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $7.56M derived: sum of 2 quarters · filed 2021-10-29 | $9.51M 10-Q · filed 2021-10-29 | $10.09M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $3.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $5.35M 10-Q · filed 2021-08-06 | $5.93M derived: sum of 3 quarters · filed 2022-03-01 | $6.84M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $1.96M 10-Q · filed 2021-05-06 | $2.53M derived: sum of 2 quarters · filed 2022-03-01 | $3.44M derived: sum of 3 quarters · filed 2022-03-01 | $3.82M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $577.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.49M derived: sum of 2 quarters · filed 2022-03-01 | $1.87M derived: sum of 3 quarters · filed 2022-03-01 | $2.06M 10-K · filed 2022-03-01 |
| 2019-09-30 | $912.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.29M derived: sum of 2 quarters · filed 2020-11-12 | $1.48M 10-Q · filed 2020-11-12 | $1.59M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $377.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $567.00K 10-Q · filed 2020-08-14 | $675.00K derived: sum of 3 quarters · filed 2021-03-01 | $695.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $190.00K 10-Q · filed 2020-05-12 | $298.00K derived: sum of 2 quarters · filed 2021-03-01 | $318.00K derived: sum of 3 quarters · filed 2021-03-01 | $332.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $128.00K derived: sum of 2 quarters · filed 2021-03-01 | $142.00K derived: sum of 3 quarters · filed 2021-03-01 | $155.00K 10-K · filed 2021-03-01 |
| 2018-09-30 | $20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $34.00K derived: sum of 2 quarters · filed 2019-11-12 | $47.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $27.00K 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $13.00K 10-Q · filed 2019-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |